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Abstract
The gold-standard method for quantifying neutralizing antibody responses to many viruses,
including dengue virus (DENV), is the plaque reduction neutralization test (PRNT, also
called the immunofocus reduction neutralization test). The PRNT conducted on 96-well
plates is high-throughput and requires a smaller volume of antiserum than on 6- or 24-well
plates, but manual plaque counting is challenging and existing automated plaque counters
are expensive or difficult to optimize. We have developed Viridot (Viridot package), a pro-
gram for R with a user interface in shiny, that counts viral plaques of a variety of phenotypes,
estimates neutralizing antibody titers, and performs other calculations of use to virologists.
The Viridot plaque counter includes an automatic parameter identification mode (misses
<10 plaques/well for 87% of diverse DENV strains [n = 1521]) and a mode that allows the
user to fine-tune the parameters used for counting plaques. We compared standardized
manual and Viridot plaque counting methods applied to the same wells by two analyses and
found that Viridot plaque counts were as similar to the same analyst’s manual count (Lin’s
concordance correlation coefficient, ρc = 0.99 [95% confidence interval: 0.99–1.00]) as man-
ual counts between analysts (ρc = 0.99 [95% CI: 0.98–0.99]). The average ratio of neutraliz-
ing antibody titers based on manual counted plaques to Viridot counted plaques was 1.05
(95% CI: 0.98–1.14), similar to the average ratio of antibody titers based on manual plaque
counts by the two analysts (1.06 [95% CI: 0.84–1.34]). Across diverse DENV and ZIKV
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strains (n = 14), manual and Viridot plaque counts were mostly consistent (range of ρc =
0.74 to 1.00) and the average ratio of antibody titers based on manual and Viridot counted
plaques was close to 1 (0.94 [0.86–1.02]). Thus, Viridot can be used for plaque counting
and neutralizing antibody titer estimation of diverse DENV strains and potentially other
viruses on 96-well plates as well as for formalization of plaque-counting rules for standardi-
zation across experiments and analysts.
Author summary
Although the plaque reduction neutralization test (PRNT) is an important assay for mea-
suring neutralizing antibody responses against many viruses, no free, open-source pro-
grams specifically designed for virus plaque counting and neutralizing antibody titer
estimation are available. We have developed Viridot, a package for R with a user-interface
in shiny, which is designed for use by laboratory-based virologists and researchers with
minimal coding experience. The program includes: automatic and user-specification of
settings for plaque counting; saving of plaque counting settings; counting of many plates
at once; and easy output of plaque counts, plaque sizes, and images with counted plaques
circled. Viridot also includes programs to analyze plaque counts, including estimation of:
neutralizing antibody titers, pfu/mL of a virus stock, and the dilution factor of virus
needed for an experiment. Viridot can be used to standardize plaque-counting methods
within and between laboratories, helping researchers formalize an important aspect of the
PRNT method that is often subjective. Viridot thus provides laboratory researchers
around the world with a free tool to improve the speed and consistency with which the
PRNT is conducted, aiding the public health response to emerging viral diseases.
Introduction
The plaque reduction neutralization test (PRNT), developed in 1956 [1], remains the gold-
standard method for measuring neutralizing antibodies against many pathogens. The PRNT
was adapted for the study of dengue viruses 1–4 (DENV1-4) in 1967 [2] and has since been
further adapted [3] and extensively used in dengue cohort studies [4–8]. The PRNT with
immunostain-based detection of plaques is used as the primary assay for measuring immuno-
genicity of dengue vaccines and vaccine candidates [9–12]. The PRNT for DENV as recom-
mended by the World Health Organization (WHO) consists of serial dilutions of antiserum
incubated with a standard concentration of virus (40–60 plaque-forming units [pfu]) inocu-
lated onto a cell monolayer on 6- or 24-well plates and incubated for 4–7 days to allow plaque
growth [13]. Plaques are revealed either by applying a vital stain to cells (some reserve the term
PRNT for this method) or by detecting plaques using a DENV-specific monoclonal antibody
(some call this the immunofocus or focus reduction neutralization test, or FRNT) [13]. The
terms PRNT and plaque are used here, consistent with the definition of ‘plaque’ provided in
Fields Virology as a lytic or non-lytic ‘area of infection’. Despite common usage, we do not use
the term ’focus’, defined in Fields Virology as ’a pile of transformed cells’ caused by infection
with tumor-causing virus, as this is not an accurate description of DENV infection [14]. WHO
recommends counting DENV plaques manually [13], generally directly from the plate or
under a microscope. It is desirable to use 96-well plates for the PRNT, which require smaller
volumes of antiserum and fewer days for plaque growth (2–4 days). However, to achieve the
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target number of pfu/well, plaques must be smaller to prevent plaque overlap [3] and thus are
more difficult to count manually.
Automated counters for immunostained plaques do exist, but current versions also present
multiple challenges. With commercial plaque counting software such as the ImmunoSpot and
Biospot software on CTL Analyzers (Cellular Technology Ltd.), researchers typically optimize
a small panel of strains for plaque intensity and size and develop programs or macros to count
plaques for each of these strains [15,16]. However, for researchers working with diverse strains
with varied plaque phenotypes, such programs are often difficult to optimize and standardize.
Additionally, commercial counters are often proprietary and expensive. Free, open-source
general image processing tools are available that allow for plaque counting on a personal com-
puter, such as ImageJ [17], but these programs require users to navigate through a series of
menu bars to identify relevant image processing tools or write their own macros; further, as
the code is written in JavaScript, many researchers may struggle to adapt image-processing
code beyond what is available. To our knowledge, there are not programs that include inte-
grated plaque counting and neutralization titer estimation functionality.
We have designed Viridot (Viridot package), a free, open-source, automated package in R
[18] for immunostained viral plaque counting and neutralizing antibody titer estimation with a
user interface in shiny [19] and image processing tools from the EBImage package [20]. The R
statistical framework is open source statistical software with a large community of users that
contribute packages enabling a multitude of specific functions. Viridot is designed to be rela-
tively simple to set up and learn for new users without coding experience as well as easy to opti-
mize to each assay. Among other features, Viridot includes plaque counting with an automatic
parameter identification mode; a single interface that enables easy access to all modifiable
parameters at once; tools to break down each image-processing step to aid in the optimization
process; counting of single or multiple plates; and the ability to save images with circled plaques
as well datasets of plaque sizes, parameter settings, and plaque counts in 96- or 24-well plate for-
mat. The Viridot plaque counter can be used for images acquired with different light settings as
well as spots of different stain colors. Viridot also has a built-in neutralizing antibody titer esti-
mation program with many modifiable parameters and programs for estimating virus concen-
trations from virus titration assays as well as the dilution factor to achieve the correct number of
pfu/well in a neutralization test.
Here, we describe the Viridot programs, explain the process for standardizing manual and
Viridot plaque counting methods, and evaluate the performance of Viridot on a variety of pla-
que images. We show that for the same set of wells, a single analyst can achieve plaque counts
with Viridot that are as similar to their own manual count as to the manual count of a different
analyst. Further, we show that neutralizing antibody titers estimated from Viridot plaque
counts are highly similar to those estimated from manual counts.
Methods
Ethics statement
This study followed the National Institutes of Health guidelines for the humane treatment of lab-
oratory animals and was approved by the NIAID Animal Care and Use Committee (11DEN33
and 14DEN34, parent protocol NIAID ASP LID 9). Human sera from NIH monovalent and tet-
ravalent DENV vaccines trials (ClinicalTrials.gov identifiers: NCT00473135, NCT00920517,
NCT00831012, NCT01072786) were performed under an investigational new drug application
reviewed by the U.S. Food and Drug Administration and approved by the Institutional Review
Board at the University of Vermont and Johns Hopkins University. Johns Hopkins Bloomberg
School of Public Health approved the study and collection of a DENV-positive human antiserum
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and coordinated the IRB review conducted by Western Institutional Review Board. Additional
human sera were collected from the NIAID vaccine study for Tick-Borne Encephalitis Virus
study (ClinicalTrials.gov identifier NCT01031537). In all studies, informed written consent was
obtained in accordance federal and international regulations (21CFR50, ICHE6).
Viridot development and distribution
Viridot was written in R 3.3.2 (R Foundation for Statistical Computing [18]). We used shiny
[19] and shinyFiles [21] for creating the user interface and the EBImage package [20] for many
of the image processing tools. Viridot is available on GitHub at: https://github.com/
leahkatzelnick/Viridot. Installation instructions for Mac and Windows are available on the
GitHub webpage and in the Viridot manual (S1 Supporting File).
Importing and exporting files and data
Through the shiny interface the user can load previous parameter settings and save current
parameter settings (mixedsort and file_ext from gtools [22]). The user is able to analyze images
from multiple plates, subsets of wells on a plate, or single wells (jpeg, jpg, png, tiff, tif, and CTL
files can be analyzed). After running the plaque counter, the user can print images with circled
plaques (paintObjects [20]), tables of plaque counts organized in 24- or 96-well plate format or
as a list, and tables of plaque radius or area (computeFeatures.shape [20]) for each well.
Image processing pipeline
The user has the option of seeing how the image data is affected by the parameter settings for
each image-processing step with the Show what is done at each step option as part of the opti-
mization process (S1 Fig). The image-processing steps are as follows. The Viridot plaque-
counting program analyzes pixel intensity values ranging from 0–1, requiring conversion of
the raw image data into a single channel that can be analyzed as a grayscale image. The amount
and type of light used for taking the well image determines the optimal color channel that pro-
vides the most information on the difference between background (should be closer to values
of 0, or dark) and plaque (closer to values of 1, or light). The user can select the red, green, or
blue channels, hue, saturation, or value channels (rgb2hsv function in the grDevices package),
or a combination of these channels. Images can then be smoothed to reduce noise by applying
a Gaussian blur (gblur, EBImage package [20]) with a sigma value (radius in pixels for the
Gaussian transformation) defined by the user. An extra option allows removal of strings or
fibers in image that are a different color from plaques. Because well edges may contain reflec-
tions, excess liquid, and other distortions that can interfere with the plaque counting, images
can be trimmed so that only pixels more than a certain distance from the well edge are
included in the analyses. To increase the difference between background and plaque, pixel
data can be transformed by multiplying and/or exponentiating the image pixel data by con-
stants, ensuring that the subsequent threshold step is applied to the pixel difference between
background and plaque, and not in some other minimum in pixel intensities. A thresholding
function with a square thresholding filter (makeBrush and thresh [20]) is used to analyze the
transformed image to identify plaque shapes. Plaque shapes from the thresholding step can be
dilated (dilate [20]) to consolidate plaques that may be broken into multiple small objects. Dis-
tinct plaques that are touching can be divided using a watershed function (distmap and water-
shed [20]), with user-specified tolerance for touching objects. Finally, the user specifies the
minimum and maximum size of an object (total number of pixels per object) that should be
counted as a plaque.
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Automatic parameter-identification mode
The Viridot automatic parameter identification mode analyzes the image for each well to iden-
tify parameters that best distinguish plaques from background for that well. Darkness and size
of the plaque (pixels with intensity>0.8)/(pixels with intensity>0.5), and the amount of back-
ground (peak in the histogram of pixel intensities), are estimated. These parameters are used
to identify parameter settings for the Gaussian blur, image transformation, and thresholding
(See Viridot manual in S1 Supporting File).
Neutralizing antibody titer estimation
The neutralizing antibody titer estimation program creates dose-response curves (2- or
3-parameter logistic regression with drm in drc package [23]) from a table of plaque counts
based on a plate template specifying the positions of samples, dilutions, and controls as defined
by the user (Viridot manual in S1 Supporting File). The user can select from multiple methods
for estimating neutralization titers, write in sample and experiment names, define the dilution
series, designate the PRNT titer cut-off (PRNT10 –PRNT90), or run only single titrations at
once. Control well plaque counts can be inserted manually or estimated from specified wells
on the plate. The program outputs the PRNT titers with 95% confidence intervals, the curve
slope, and a plot showing the neutralization curves with 95% confidence intervals, with cus-
tomizable color schemes and methods for plotting error bars of the raw data. A program simi-
lar to the LID Statistical Web Tools Plaque Reduction tab (https://exon.niaid.nih.gov/
plaquereduction/) is also available for PRNT titer estimation.
Other Viridot tools
Tools for estimating the virus dilution required for neutralization tests (e.g. 40 pfu/well) and a tool
for estimating virus titer (pfu/mL) from a virus titration are also included in the Viridot package.
Image formatting
This tab allows the user to cut an image of multiple wells into individual square well images,
enabling users to more easily use camera phones for well image acquisition. The user can also
trim individual well images to square images.
Standardized rules for manual and Viridot plaque counting
Standardized manual plaque counting rules were established by having four analysts discuss
the plaque counting process for a well of plaques with uniform size and intensity (S2A Fig) as
well as non-uniform size and intensity (S2B Fig). The following rules were established. (1) All
spots either totally or partially within the specified well area were counted. (2) Spots more than
approximately twice the size of the average dark spot were divided using reasonable break-
points. (3) Pale spots about the size of the average spot were counted as plaques. 4) Spots less
than approximately half the size of the average spot and non-blue artifacts (e.g. strings or
fibers) were not counted.
We also developed rules for optimizing plaque-counting parameters for Viridot. (1) Run
the automatic parameter identification mode with plaques counted within circle�25 pixels
from the image edge. (2) Identify the well on the plate expected to be most poorly counted by
the plaque counter, and modify the following parameter settings (in the user-adjustable
mode), in this order: (i) Gaussian blur (decreased), (ii) contrast, (iii) threshold, (iv) dividing
overlapping plaques, (v) minimum plaque size (increased), and (vi) dilation (decreased). (3)
Once a satisfactory count was achieved, the user assessed three additional random wells to
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check the final quality of the plaque count and make any additional adjustments. The final
parameter settings were then applied to count plaques for the full plate.
Data sets
The automatic-parameter identification mode training set and test set 1 each consisted of 1521
well images of PRNT titrations conducted on C6/36 cells (Aedes albopictus, NIAID/Novavax
MCB) (full PRNT protocol in S2 Supporting File). The PRNT titrations were of 47 genetically
diverse DENV1-4 strains (GenBank accession numbers KT382187, KT452791, GQ868619,
FJ639680, AY145121, AY780643, EU482591, AF180817, KT382186, FJ461335, KT382189,
KT452795, GU131927, GQ868638, KT382188, FJ538920, FJ467493, AF038403, EU482756,
EU482684, AY158339, EF105384, AY744147, KT452797, KT452796, EU482672, KT452792,
KT452799, L11422, KT452798, HQ541806, KT452800, EU529698, EU660409, FJ432743,
KT452794, KT452793, KF543272, KT452802, AF326573, JN022608, KT452801, JF262780,
KT452803, EU854297, FJ882599, and AY780644) titrated against de-identified human bioreposi-
tory samples from prior clinical trials of monovalent components of a live attenuated dengue vac-
cine [24] or African green monkey (Chlorocebus sabaeus, NHP) antisera [25]. The training set
consisted of well E7 from each plate; test set 1 was well H9. Test set 2 consisted of 421 additional
well images randomly drawn from the control antiserum titration plate for PRNT titrations of the
African green monkey antisera against 107 Thai DENV1-4 strains (subset of strains in [26], Gen-
Bank accession numbers KY586306 to KY586946) that had not been used in the training set or in
test set 1. The manual plaque-counting methods comparison (n = 72 wells) and Viridot plaque-
counting methods comparison (n = 32 wells) used 96-well plates of C6/36 cells inoculated with a
DENV3 strain (GenBank accession number HQ541806) at a target of 40 pfu/well. Comparison of
standardized manual and Viridot plaque-counting methods consisted of 168 wells of the DENV3
strain titrated against DENV-positive antiserum (three titrations on the same plate, three titrations
on different plates in different experiments). Plaque data from titrations of African green monkey
antisera against a subset of the DENV1-4 strains on C6/36 cells (n = 240 wells [24,25]) were also
studied. All plaque data were stained with peroxidase-labeled antibody and TrueBlue peroxidase
substrate (full details in S2 Supporting File). Plates were scanned with the ImmunoSpot Analyzer
(CTL, Shaker Heights, OH), with a light source from above using the standard Costar 96 well tem-
plate for clear plates (details about the plate, camera, and light settings are provided in S1 Table).
Well images were saved as .CTL images (encrypted .tiff files) of 752 by 752 pixels.
A second laboratory used human sera (de-identified samples from a prior clinical trial of a
live attenuated dengue vaccine [27] or human monoclonal antibodies [28]) against a DENV2
strain (AF038403) and ZIKV strain (KX280026) on Vero (African green monkey kidney) cells
(n = 160). Plaques were stained with peroxidase-labeled antibody and TrueBlue peroxidase
substrate (S2 Supporting File). All plates were scanned using a Zeiss Axio Imager.M1 micro-
scope with a 2.5X lens and the AxioCam MRc mounted camera controlled by the software
KSElispot (Windows 95). Well images were saved as .TIF images of 1040 by 1040 pixels.
We also imaged plates from the top (well-side) and the bottom of 96 well plates using cam-
era phones. A set of 45 well images from clear plates (placed on white paper) were taken using
the iPhone 7 plus version 11.4.1, model MN5L2LL/A, without flash. The camera phone was
balanced on a plastic test tube holder 9cm above the plate, with bench lighting 39 cm above
plate. Five additional well images taken from the top of white 96 well plates were acquired
using the Samsung Galaxy S7, model SM-G930V, also without flash. Camera phone images
were divided into individual wells using the crop function in Preview and trimmed to square
images using the Viridot image formatting program. Images ranged in size but were a mini-
mum of 200 by 200 pixels to ensure sufficient resolution for counting.
Viridot: An automated virus plaque counter
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A small panel of wells that captured a more diverse array of light and staining methods were
also analyzed. A well of ZIKV plaques on Vero cells was acquired using the Zeiss Axio Imager.M1
microscope with a 2.5X lens and the AxioCam MRc mounted camera, using bright top lighting.
A well of IFN-γ T-cell responses to Influenza A nucleoprotein (NP) peptide 147–155 was measured
using an IFN-γ specific biotinylated monoclonal antibody stained with phosphate-labeled strepta-
vidin and 5-bromo, 4-chloro, 3-indolylphosphate/nitroblue tetrazolium substrate [29,30]. The
image was taken with Zeiss Axio Cam Imager.M2 scope with the AxioCam MRc camera, 5x
objective lens (image courtesy of J. Misplon). A well of the total and DENV4-specific IgG+ mem-
ory B cells were from an ELISPOT-based Multi-Color FluoroSpot assay [31]. Spots were detected
by adding either a TRITC-labeled IgG-specific antibody or antigen of each serotype and virus-
specific antibodies each labeled with a fluorescent Qdot of a different color. Images were acquired
using the ImmunoSpot Analyzer (images courtesy of P. Andrade). Wells of plaques of recombi-
nant lymphocytic choriomeningitis virus (LMCV) on Vero E6 cells were resolved by applying
crystal violet and ethanol in water [32]. Plates were imaged using Alpha Innotech digital camera
with the Computar H6Z0812M motorized zoom lens and divided into individual well images
using the Viridot image formatting program (images courtesy of C. Ziegler).
Statistical analyses
The Viridot automatic parameter identification mode was evaluated by having an analyst classify
counted well images by number of missing plaques in the following ranges: 0, 1–3, 4–7, 8–14,
15–19, 20–30,>30. Absolute number of plaques missed and the proportion of plaques missed
(automatic count/[plaques missed + automatic count]) for the training and test sets are presented
as pie charts.
For comparisons of manual and Viridot counts, exact numbers of plaques were counted.
Agreement between analysts for each method or for a given analyst between methods was esti-
mated with Lin’s concordance correlation coefficient, ρc, a measure of the extent to which
observations deviate from a line with slope 1, intercept 0 (45˚ line through origin) with ρc=1
indicating perfect concordance, -1 perfect discordance, and 0 no concordance (values�90%
indicate good concordance). We also estimated the ratio of plaque counts by different methods
to enable evaluation of bias toward overcounting by Viridot (e.g., Manual:Viridot ratio less
than 1) or undercounting by Viridot (e.g., Manual:Viridot ratio greater than 1). For both mea-
sures, 95% confidence intervals are shown (95%CI). We also estimated the ratio of PRNT50
titers with 95% confidence intervals for titrations with plaques counted by different methods.
PRNT50 titers were estimated without allowing for a resistant fraction, without using the LID
Statistical Web Tools method, and using the ’eachtop’ setting for defining plaque counts in the
absence of neutralization. To summarize results across experiments, we present geometric
averages of the ratios of plaque counts as well as PRNT50 titers; ratios that include 1 in the con-
fidence interval indicate there is not a significant difference between methods.
Results
Viridot was developed using PRNT data of genetically diverse DENV strains in>100,000 plaque
well images from experiments conducted over many years. Most well images were of plaques on
clear 96 well plates immunostained with peroxidase-labeled antibodies with peroxide substrate
TrueBlue. Plates were imaged with CTL ImmunoSpot Analyzer and saved as square .TIF and .JPG
images of more than 500 by 500 pixels. Examples of well images that capture the range of plaque
phenotypes used for developing Viridot and optimizing the automatic parameter identification
mode, along with corresponding images of counted plaques, are shown in Fig 1.
Viridot: An automated virus plaque counter
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To enable the user to optimize the Viridot plaque counting program (Fig 2) to count diverse
virus plaque phenotypes, we incorporate two main features: 1) an automatic parameter identi-
fication mode to help the user have the best ‘first pass’ parameters for counting particular well
images and 2) user adjustment of parameter settings, with the option of seeing the effect of
each step in the image processing pipeline, to enable the user to fine-tune parameters for that
particular virus or experiment.
Evaluation of the automatic Viridot plaque counter parameter-
identification mode
The automatic parameter-identification mode was developed using a training set (n = 1521
well images) of plaques of genetically diverse DENV1-4 strains. The automatic mode missed
<10 plaques/well for 84% of the training set and achieved a plaque count�80% of the analyst-
classified count for 86% of the training set (Fig 3). The quality of the Viridot automatic pro-
gram was evaluated for a different randomly selected well from the same 1521 plates (test set
1) and for 421 additional well images of plaques from 107 DENV strains not used in the train-
ing set (test set 2). For test set 1 and 2, 87% and 87%, respectively, of automatically-counted
wells missed <10 plaques and 90% and 83%, respectively, of wells had�80% the number of
plaques of the analyst-classified count (Fig 3).
Standardization of manual and Viridot parameter adjustment methods for
plaque counting
Two analysts (designated A1 and A2) each counted the same 72 wells of DENV3 plaques
directly from the plate, under a microscope, and from the printed image of the well (752 by
Fig 1. Example well images of DENV and ZIKV plaques and resulting Viridot plaques counts. The type of camera used for acquiring the image, cell type for infection,
and the virus (with location and year of isolation) is printed above each raw image. The image in which plaques have been counted is shown below, with the resulting
plaque count printed in the top left corner. Well images reflect separate experiments done by different analysts.
https://doi.org/10.1371/journal.pntd.0006862.g001
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752 pixels) with a circle of constant radius within which plaques were to be counted. We mea-
sured within and between analyst variation in plaque counting using ρc, which measures devia-
tion from perfect concordance, as well as ratio of plaque counts (Table 1). For both A1 and A2,
within-analyst concordance was poor across methods (ρc<0.67 for all comparisons) but A1
and A2 had better agreement for plaque counts from the printed well image (ρc = 0.81 [95%
CI: 0.72–0.87], ratio of plaque counts, 0.96 [95% CI: 0.94–0.98]). Based on these observations,
Fig 2. The Viridot plaque counter program. The scrollable panel on the left contains the parameter settings for plaque counting and buttons to load and save parameter
settings. Selection of plates and images for analysis is shown in the center. A well containing DENV plaques is shown, with counted plaques circled in red and the well area
in which plaques were counted circled in blue. The plaque count is shown above the image. The panel to the right includes options to save plaque count tables, circled
plaque images, and plaque sizes.
https://doi.org/10.1371/journal.pntd.0006862.g002
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we developed standardized plaque counting rules by seeking consensus among four analysts
about what did and did not qualify as a plaque (see Methods).
We also evaluated within- and between-analyst differences in Viridot plaque counting
methods for an additional 36 wells of DENV3 plaques, comparing the automatic parameter-
identification and the user-adjusted parameter mode, with parameters adjusted to the same
well or wells chosen by each analyst separately (Table 2). There was good agreement between
A1 and A2 counts for the user-defined settings adjusted to the same well (0.87 [95%CI: 0.81–
0.91]), and as expected, perfect concordance for the automatic parameter identification mode.
Based on these observations, we developed a standardized protocol for optimizing user-speci-
fied settings for the Viridot counter (see Methods).
Comparison of standardized manual and Viridot plaque counts and
neutralizing antibody titers
With these standardized manual and Viridot counting methods, we compared counts within
and between analysts for an additional 168 wells of DENV3 plaques on C6/36 cells, consisting
Fig 3. Evaluation of the Viridot automatic parameter-identification mode for a training set and two test sets. Total number (A-C) or proportion (D-F) of
plaques per well image counted by the Viridot automatic parameter-identification program that are discordant with analyst-estimated plaque counts. A single
analyst estimated the number of miscounted plaques by checking raw images for plaques not circled by the automatic counter.
https://doi.org/10.1371/journal.pntd.0006862.g003
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of six titrations of a DENV-positive antiserum (three from the same plate and experiment,
three each from different plates and experiments, Tables 3 and S2 and Fig 4A). Within analyst,
manual and Viridot counts were strongly in agreement (ρc: A1 = 0.99, A2 = 1.00) with a slight
tendency of Viridot to undercount plaques (ratio of manual to Viridot counts: A1 = 1.02,
A2 = 1.04), although not significantly (Table 3). Between analysts, there was good agreement
for both the Viridot method (ρc = 0.99, ratio of plaque counts = 0.97) and the manual counting
methods (ρc = 0.99, ratio of plaque counts = 0.95, Table 3).
We also measured the consistency of neutralizing antibody titers (Fig 4B) within and
between experiments for the two analysts using the standardized manual and Viridot counted
plaque data. Neutralizing antibody titers were estimated for each of the plaque counting
Table 1. Comparison of manual plaque counting methods within and between Analyst 1 and Analyst 2 (n = 72 wells).
Within Analyst
metdods comparison
Analyst 1 Analyst 2
Concordance ρc (95% CI) Plaque count ratio (95% CI) Concordance ρc (95% CI) Plaque count ratio (95% CI)
From plate vs. under microscope 0.67
[0.53–0.78]
1.00
[0.96–1.03]
0.07
[0.01–0.13]
0.73
[0.7–0.76]
From plate vs. printed image 0.60
[0.44–0.72]
0.94
[0.91–0.97]
0.06
[-0.12–0.25]
0.90
[0.86–0.94]
Under microscope vs. printed image 0.62
[0.47–0.74]
0.94
[0.91–0.97]
0.15
[0.06–0.24]
1.23
[1.2–1.27]
Between Analysts methods comparison Analyst 1 vs. Analyst 2
Concordance ρc (95% CI) Plaque count ratio (95% CI)
From plate 0.19
[-0.04–0.4]
0.99
[0.95–1.05]
Under microscope 0.14
[0.07–0.2]
0.73
[0.70–0.76]
Printed image 0.81
[0.72–0.87]
0.96
[0.94–0.98]
Deviation from perfect concordance of 1 between methods (ρc, Lin’s concordance correlation coefficient) and geometric average ratio of plaque counts by different
methods, shown with 95% confidence intervals (95% CI).
https://doi.org/10.1371/journal.pntd.0006862.t001
Table 2. Comparison of Viridot plaque counting methods within and between Analyst 1 and Analyst 2 (n = 36 wells).
Within Analyst
methods comparison
Analyst 1 Analyst 2
Concordance ρc (95% CI) Plaque count ratio (95% CI) Concordance ρc (95% CI) Plaque count ratio (95% CI)
Auto vs. user-specified, same well 0.28
[0.15–0.39]
0.83
[0.79–0.86]
0.51
[0.39–0.61]
0.85
[0.82–0.89]
Auto vs. user-specified, any well 0.12
[0.02–0.22]
0.77
[0.73–0.81]
0.92
[0.88–0.94]
0.93
[0.91–0.94]
User-specified, same well vs. any well 0.82
[0.76–0.86]
0.93
[0.92–0.94]
0.69
[0.59–0.77]
1.08
[1.06–1.11]
Between Analysts methods comparison Analyst 1 vs. Analyst 2
Concordance ρc (95% CI) Plaque count ratio (95% CI)
Auto 1 1
User-specified, same well 0.87
[0.81–0.91]
1.03
[1.02–1.05]
User-specified, any well 0.22
[0.09–0.34]
1.21
[1.16–1.26]
Deviation from perfect concordance of 1 between methods (ρc, Lin’s concordance correlation coefficient) and geometric average ratio of plaque counts by different
methods, shown with 95% confidence intervals (95% CI).
https://doi.org/10.1371/journal.pntd.0006862.t002
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methods using the Viridot neutralization titer estimation tool (Fig 5). Overall, the geometric
average ratio of the PRNT50 for the same titration between manual and Viridot counted pla-
ques was 1.05 [95%CI: 0.98–1.14], indicating manual counted titrations had slightly higher
PRNT50 titers, although not significantly. The average ratio of A1 to A2 manual counted anti-
body titers was 1.06 [0.84–1.34], similar to the average ratio of A1 to A2 Viridot counted anti-
body titers (0.99 [0.84–1.17]). Both manual counts and Viridot counts produced neutralizing
antibody titers with 95% confidence intervals of less than a two-fold difference, with slightly
narrower confidence intervals for manual counted titrations (manual count = 0.73 ± 0.22 [log2
scale], Viridot = 0.84 ± 0.27). Neutralization curves for manual counts were closer to the Viri-
dot counts of the same titration than to manual counts of other titrations (Fig 4B–4D).
Manual and Viridot plaque counts and neutralizing antibody titers for
diverse flavivirus strains and antibody samples
To confirm that Viridot could reliably count plaques for other flavivirus strains and on different
cell substrates, plaques were counted for neutralizing antibody titrations of additional viruses
including DENV1-4 strains (n = 10 viruses) on C6/36 cells as well as a DENV2 and ZIKV strain
on Vero cells. Concordance was>0.97 for the majority of strains, although concordance for
some ZIKV and DENV1 titrations was lower (Fig 6A and S2 Table). The neutralization curves
again show good agreement between manual and Viridot counted titrations, with an average
ratio of PRNT50 titers of 0.94 [0.86–1.02] (Fig 6B and 6C and S3 Table), indicating slightly
higher average neutralizing antibody titers with Viridot, although not significantly.
Manual and Viridot plaque counts for well images taken with camera
phones
To evaluate whether Viridot could be used as part of a lower-cost image acquisition platform,
we used camera phones to image plates from the top (well-side) and bottom of 96 well plates
(Fig 7A–7C). A single photo of the bottom of a 96 well plate allowed for reliable counting of 30
wells from a single image. Overall, we observed strong concordance between manual and Viri-
dot counted plaques from camera phone images (ρc from 0.85–0.96, Fig 6D).
Diverse well images can be analyzed with Viridot
Viridot is based on standard image processing tools and thus can be easily adapted to count
images with other types of spots. Fig 7 shows well images acquired with bright lighting, from T
Table 3. Comparison of the standardized manual and Viridot plaque counting methods within and between Analyst 1 and Analyst 2 (n = 168 wells).
Within Analyst
methods comparison
Analyst 1 Analyst 2
Concordance ρc (95% CI) Plaque count ratio (95% CI) Concordance ρc (95% CI) Plaque count ratio (95% CI)
Manual vs. Viridot 0.99
[0.99–1.00]
1.02
[1.01–1.03]
0.99
[0.99–1.00]
1.04
[1.03–1.05]
Between Analysts methods comparison Analyst 1 vs. Analyst 2
Concordance ρc (95% CI) Plaque count ratio (95% CI)
Manual 0.99
[0.98–0.99]
0.95
[0.94–0.97]
Viridot 0.99
[0.99–0.99]
0.97
[0.96–0.98]
Deviation from perfect concordance of 1 between methods (ρc, Lin’s concordance correlation coefficient) and geometric average ratio of plaque counts by different
methods, shown with 95% confidence intervals (95% CI).
https://doi.org/10.1371/journal.pntd.0006862.t003
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and B cell ELISPOT assays, and from plaque assays stained using crystal violet (Fig 7D–7G).
To use Viridot on such images, the user must adjust the light setting (color channel) in step 1
of the plaque counter parameter-setting window.
Fig 4. Comparison of standardized manual and Viridot plaque counts and neutralizing antibody titers. (A) Comparison of manual and Viridot counts of DENV3
plaques on C6/36 cells for six repeat titrations of a DENV3-positive antiserum by two analysts (A1 and A2). Linear regression lines are shown for each titration and
analyst. The grey line indicates perfect correspondence. (B) PRNT50 titers with 95% confidence intervals for the six titrations counted by A1 and A2, manually and with
Viridot. Resulting neutralization curves for A1 (C) and A2 (D) for the six titrations, counted either manually (solid lines) or with Viridot (dotted).
https://doi.org/10.1371/journal.pntd.0006862.g004
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Discussion
In this study, we present Viridot (Viridot package) for R, a free, open-source suite of virology
tools with a user-interface in shiny designed for viral plaque counting as well as for neutraliz-
ing antibody titer estimation. Viridot was designed by and for laboratory-based researchers
performing DENV and ZIKV neutralizing antibody titrations with the goal of improving the
speed and consistency of the PRNT, a critical assay for measuring protective anti-flavivirus
antibodies. We demonstrate that Viridot can count plaques on well images from 96-well plates
at least as reliably as two analysts counting manually from the printed well image, suggesting
that Viridot can be used to help researchers transition to using 96-well plates for the PRNT.
Although manual plaque counting is the gold-standard approach, to our knowledge, few
studies describe the rules used for manual plaque counting or efforts to standardize counting
methods between analysts [33]. This may introduce additional variability into neutralizing
antibody titer quantification beyond factors already identified [34,35]. We show that applying
consistent rules for manual plaque counting both within and between analysts can improve
Fig 5. The Viridot neutralization titer estimation program. The scrollable panel on the left contains the parameter settings for neutralizing antibody titer estimation. In
the top-center, users can import plaque count tables and the plate template (the user can switch tabs to see the imported templates and tables). In the center, summary
statistics for control wells and the neutralizing antibody titration curves are shown, with 95% confidence intervals in blue and error bars (± 1sd shown) in gray. The
estimated neutralizing antibody titer is printed above. The panel to the right includes options to save neutralizing antibody titer data to a table and to print the image of
neutralization curves.
https://doi.org/10.1371/journal.pntd.0006862.g005
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consistency of plaque counts. An advantage of the Viridot plaque counter is that it allows users
to develop and implement exact plaque-counting rules and apply those rules consistently
Fig 6. Comparison of manual and Viridot counts of DENV1-4 and ZIKV plaques and neutralizing antibody titers on C6/36 cells or Vero cells. (A) Comparison of
standardized manual and Viridot plaque counts, with linear regression (solid lines) showing concordance: ρc values for each titration are indicated in the legend. The
dotted black line indicates perfect correspondence. (B and C) Resulting neutralization curves for each antiserum titration, counted either manually (solid lines) or with
Viridot (dotted). The geometric average ratio of the manual to Viridot for all PRNT50 titers is 0.94 (95% CI: 0.86–1.02). (D) Comparison of standardized manual and
Viridot counted plaques in well images acquired using camera phones. Linear regression lines (solid lines), concordance (ρc) values for plaque data of each image type
(legend), and perfect correspondence (black dotted line) are shown.
https://doi.org/10.1371/journal.pntd.0006862.g006
Viridot: An automated virus plaque counter
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006862 October 24, 2018 15 / 20
across wells and plates, reducing the risk of operator bias and variation amongst analysts even
in the same laboratory. On average, manual and Viridot counted plaques and PRNT50 titers
were not significantly different. However, for certain titrations, including for certain viruses,
Viridot did significantly deviate from manual counts, suggesting that inaccurate counting can
occur. Undercounting mostly occurs for wells with large, irregularly shaped clusters of plaques
that Viridot counts as a single plaque, while overcounting is most common in wells with pale
plaques that are close in color intensity to background. Adjustment of parameter settings can
help but may still be imperfect. Users should check Viridot counts of well images against their
Fig 7. Viridot counting of camera phone well images and spots acquired using other staining methods. (A and B) Images of DENV4 plaques on C6/36 cells
(peroxidase-labeled antibody and TrueBlue stain) acquired using the iPhone 7 plus of the bottom and top of the plate. (C) Images of ZIKV plaques on Vero cells on white
plates, with images acquired using the Samsung Galaxy S7. (D) Images of ZIKV plaques on Vero cells acquired using the Zeiss Axio Imager.M1 microscope, using bright
top lighting. (E) IFN-γ ELISPOT of the T-cell response to Influenza A nucleoprotein peptide 147–155, imaged with the Zeiss Axio Cam Imager.M2 scope with the
AxioCam MRc camera, 5x objective lens. (F) Total (left) and DENV4-specific IgG+ memory B cells (right). Spots were detected with TRITC-labeled IgG-specific antibody
or Qdot-conjugated fluorescent antibody using an ELISPOT based Fluorospot, with images acquired using the ImmunoSpot Analyzer. (G) LCMV plaques on Vero E6
cells resolved using crystal violet and imaged using the Alpha Innotech digital camera with the Computar H6Z0812M motorized zoom lens.
https://doi.org/10.1371/journal.pntd.0006862.g007
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rules for manual counting to ensure the program is optimized to reflect user judgment about
what constitutes a plaque.
Viridot provides some advantages over other existing tools. CTL Analyzer software and
ImageJ require more extensive parameter optimization (clicking through menu-bars to iden-
tify all modifiable parameters) for each plaque phenotype, making them efficient programs for
protocols using a few prototype strains but inconvenient for working with large numbers of
diverse viral strains with distinct plaque phenotypes. Viridot has parameters readily accessible
and organized in a single scroll bar, making optimization easier, and can be used for analysis
of a diverse array of plaque phenotypes as well as for other immunostained spots. Further, the
source code for the CTL ImmunoSpot Analyzer software is proprietary, and ImageJ is written
in JavaScript, a language with which many laboratory-based researchers may not be familiar.
Viridot is open-source and written in R, a statistical language used widely by biologists, poten-
tially making it easier for researchers to modify the program for their own means. Further,
while commercial counters have high-quality hardware for acquiring images of each well, they
are expensive. We show that Viridot can analyze camera phone images, making it potentially
useful in low-resource settings as part of an inexpensive plaque counting pipeline. With further
development and standardization, Viridot may be useful in settings that involve stringent
requirements such as the assay validation required for clinical trials or hospital settings.
Viridot has some limitations. The Viridot plaque counter was not fully optimized for all
light and cellular conditions, and thus may perform better under some conditions than others.
Unlike the ImmunoSpot Analyzers, Viridot does not have an interactive interface for quality
control or manually removing incorrectly counted plaques. Viridot is not a commercial prod-
uct and thus does not have a warranty.
Overall, Viridot was developed as a tool for researchers measuring neutralizing antibody
responses to viruses using immunostain-based plaque reduction assays. Viridot has multiple
advantages over manual plaque counting as well as other automated programs, enabling rapid
counting of diverse viral strains on 96-well plates as well as a framework for formalizing pla-
que-counting rules to improve the consistency across experiments, analysts, and laboratories.
Supporting information
S1 Fig. The effect of each image-processing step in the Viridot plaque counting pipeline is
shown from the original raw well image to the counted well image. The user can visualize
each step using the "Show what is done at each step" option in the interface. Step 1: select light
setting. Step 2: blur image (extra option to remove strings/fibers in image at this stage). Step 3:
cut well edges and insert value for pixels outside well. Step 4: apply contrast to image based on
background and plaque intensity. Step 5: select difference in pixel value to distinguish plaque
from background and size (in pixels) of the window for applying the thresholding algorithm to
the image. Step 6: dilate plaques to ensure they are counted as single objects. Step 7: cut over-
lapping plaques so they are counted separately. Step 8: define the minimum and maximum
pixel size to count as a plaque. Details are provided in the Step-by-step guide to optimizing pla-
que counter parameter settings section of the Viridot manual (S1 Supporting File).
(PDF)
S2 Fig. Comparison of manual plaque counts among analysts. Manual plaque counting by
four separate analysts for (A) a well of uniform, evenly colored plaques or (B) a well of plaques
with non-uniform size and intensity.
(PDF)
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S1 Table. Plate, camera, and color settings used for taking images of plaques using a CTL
Immunospot Analyzer, corresponding to the Costar 96 well template built into the soft-
ware.
(DOCX)
S2 Table. Manual and Viridot plaque count comparison as shown in Figs 5 and 6.
(DOCX)
S3 Table. Neutralizing antibody titers (PRNT50) estimated with manual and Viridot pla-
que counting (Data correspond to Fig 6).
(DOCX)
S1 Supporting File. The Viridot manual.
(PDF)
S2 Supporting File. PRNT and image acquisition protocols.
(PDF)
S1 Supporting Data. A .zip file that includes plaque count data used for Figs 5 and 6.
(ZIP)
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